Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update

Kelvin L. Chou; Justin Martello; Juliana Atem; Matt Elrod; Erin R. Foster; Karen Freshwater; Steven A. Gunzler; Hojoong Kim; Abhimanyu Mahajan; Harini Sarva; Glenn T. Stebbins; Erin Lee; Laurice Yang

doi:10.1212/WNL.0000000000012198

Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update

Kelvin L. Chou, Justin Martello, Juliana Atem, Matt Elrod, Erin R. Foster, Karen Freshwater, Steven A. Gunzler, Hojoong Kim, Abhimanyu Mahajan, Harini Sarva, Glenn T. Stebbins, Erin Lee, Laurice Yang

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Parkinson disease (PD) is the second most common neurodegenerative disorder, after Alzheimer disease,1 and the number of individuals with PD worldwide more than doubled between 1990 and 2015.2 In 2016, PD affected an estimated 6.1 million people globally.3 In the United States, an estimated 680,000 individuals ≥45 years of age had PD in 2010.4 These numbers were projected to rise to 930,000 in 2020 and to reach 1,238,000 by 2030.4 Both motor (rest tremor, bradykinesia, rigidity) and nonmotor (including but not limited to neuropsychiatric, autonomic, and sensory) symptoms of PD contribute to decreased quality of life5 and neurologic disability.3

Original language	English
Pages (from-to)	239-245
Number of pages	7
Journal	Neurology
Volume	97
Issue number	5
DOIs	https://doi.org/10.1212/WNL.0000000000012198
State	Published - Aug 3 2021

Access to Document

10.1212/WNL.0000000000012198

Cite this

@article{79b5c3c529744d5ba61986368d12b323,

title = "Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update",

abstract = "Parkinson disease (PD) is the second most common neurodegenerative disorder, after Alzheimer disease,1 and the number of individuals with PD worldwide more than doubled between 1990 and 2015.2 In 2016, PD affected an estimated 6.1 million people globally.3 In the United States, an estimated 680,000 individuals ≥45 years of age had PD in 2010.4 These numbers were projected to rise to 930,000 in 2020 and to reach 1,238,000 by 2030.4 Both motor (rest tremor, bradykinesia, rigidity) and nonmotor (including but not limited to neuropsychiatric, autonomic, and sensory) symptoms of PD contribute to decreased quality of life5 and neurologic disability.3",

author = "Chou, {Kelvin L.} and Justin Martello and Juliana Atem and Matt Elrod and Foster, {Erin R.} and Karen Freshwater and Gunzler, {Steven A.} and Hojoong Kim and Abhimanyu Mahajan and Harini Sarva and Stebbins, {Glenn T.} and Erin Lee and Laurice Yang",

note = "Publisher Copyright: {\textcopyright} American Academy of Neurology.",

year = "2021",

month = aug,

day = "3",

doi = "10.1212/WNL.0000000000012198",

language = "English",

volume = "97",

pages = "239--245",

journal = "Neurology",

issn = "0028-3878",

number = "5",

}

TY - JOUR

T1 - Quality Improvement in Neurology

T2 - 2020 Parkinson Disease Quality Measurement Set Update

AU - Chou, Kelvin L.

AU - Martello, Justin

AU - Atem, Juliana

AU - Elrod, Matt

AU - Foster, Erin R.

AU - Freshwater, Karen

AU - Gunzler, Steven A.

AU - Kim, Hojoong

AU - Mahajan, Abhimanyu

AU - Sarva, Harini

AU - Stebbins, Glenn T.

AU - Lee, Erin

AU - Yang, Laurice

PY - 2021/8/3

Y1 - 2021/8/3

N2 - Parkinson disease (PD) is the second most common neurodegenerative disorder, after Alzheimer disease,1 and the number of individuals with PD worldwide more than doubled between 1990 and 2015.2 In 2016, PD affected an estimated 6.1 million people globally.3 In the United States, an estimated 680,000 individuals ≥45 years of age had PD in 2010.4 These numbers were projected to rise to 930,000 in 2020 and to reach 1,238,000 by 2030.4 Both motor (rest tremor, bradykinesia, rigidity) and nonmotor (including but not limited to neuropsychiatric, autonomic, and sensory) symptoms of PD contribute to decreased quality of life5 and neurologic disability.3

AB - Parkinson disease (PD) is the second most common neurodegenerative disorder, after Alzheimer disease,1 and the number of individuals with PD worldwide more than doubled between 1990 and 2015.2 In 2016, PD affected an estimated 6.1 million people globally.3 In the United States, an estimated 680,000 individuals ≥45 years of age had PD in 2010.4 These numbers were projected to rise to 930,000 in 2020 and to reach 1,238,000 by 2030.4 Both motor (rest tremor, bradykinesia, rigidity) and nonmotor (including but not limited to neuropsychiatric, autonomic, and sensory) symptoms of PD contribute to decreased quality of life5 and neurologic disability.3

UR - http://www.scopus.com/inward/record.url?scp=85113596256&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000012198

DO - 10.1212/WNL.0000000000012198

M3 - Article

C2 - 34341076

AN - SCOPUS:85113596256

SN - 0028-3878

VL - 97

SP - 239

EP - 245

JO - Neurology

JF - Neurology

IS - 5

ER -

Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update

Abstract

Access to Document

Other files and links

Fingerprint

Cite this